Evidence map›Paper›PMID 33208397›Full record

Observational studyArchives of disease in childhood2021

Development and validation of a prediction model for invasive bacterial infections in febrile children at European Emergency Departments: MOFICHE, a prospective observational study.

Nienke N Hagedoorn, Dorine Borensztajn, Ruud Gerard Nijman, Daan Nieboer, Jethro Adam Herberg, Anda Balode, Ulrich von Both, Enitan Carrol, Irini Eleftheriou, Marieke Emonts and 14 more

Open access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Archives of disease in childhood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Inter-specialty differences in the management of febrile neonates on prostaglandin E1.Journal of perinatology : official journal of the California Perinatal Association · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Observational
  8. Observational
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 6 countries.

Nienke N HagedoornGeneral Paediatrics, Erasmus MC Sophia Children's Hospital, Rotterdam, Zuid-Holland, The Netherlands.ORCID 0000-0001-9237-4904
Dorine BorensztajnGeneral Paediatrics, Erasmus MC Sophia Children's Hospital, Rotterdam, Zuid-Holland, The Netherlands.ORCID 0000-0002-2437-0757
Ruud Gerard NijmanSection of Paediatric Infectious Diseases, Imperial College London, London, UK.ORCID 0000-0001-9671-8161
Daan NieboerPublic Health, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands.
Jethro Adam HerbergSection of Paediatric Infectious Diseases, Imperial College London, London, UK.ORCID 0000-0001-6941-6491
Anda BalodePaediatrics, Children clinical university hospital, Rigas Stradinas Universitate, Riga, Latvia.
Ulrich von BothDivision of Paediatric Infectious Diseases, Dr von Haunersches Kinderspital Kinderklinik und Kinderpoliklinik der Ludwig Maximilian Universitat Munchen, Munchen, Bayern, Germany.ORCID 0000-0001-8411-1071
Enitan CarrolInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, Merseyside, UK.
Irini EleftheriouSecond Department of Paediatrics, P & A Kyriakou Children's Hospital, National and Kapodistrian University of Athens, Athinon, Greece.
Marieke EmontsPaediatric Immunology, Infectious Diseases & Allergy, Great North Children's Hospital, Newcastle upon Tyne, UK.
Michiel van der FlierPaediatric Infectious Diseases and Immunology, Amalia Children's Hospital, Radboudumc, Nijmegen, Gelderland, The Netherlands.
Ronald de GrootPaediatric Infectious Diseases and Immunology, Amalia Children's Hospital, Radboudumc, Nijmegen, Gelderland, The Netherlands.
Benno KohlmaierDepartment of General Paediatrics, Medical University of Graz, Graz, Steiermark, Austria.
Emma LimPaediatric Immunology, Infectious Diseases & Allergy, Great North Children's Hospital, Newcastle upon Tyne, UK.
Ian MaconochiePaediatric Emergency Medicine, Imperial College Healthcare NHS Trust, London, UK.
Federico Martinón-TorresGenetics, Vaccines, Infections and Paediatrics Research group (GENVIP), Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.
Marko PokornDepartment of Infectious Diseases and Faculty of Medicine, Ljubljanski Univerzitetni klinicni center, Ljubljana, Slovenia.
Franc StrleDepartment of Infectious Diseases and Faculty of Medicine, Ljubljanski Univerzitetni klinicni center, Ljubljana, Slovenia.
Maria TsoliaSecond Department of Paediatrics, P & A Kyriakou Children's Hospital, National and Kapodistrian University of Athens, Athinon, Greece.
Dace ZavadskaPaediatrics, Children clinical university hospital, Rigas Stradinas Universitate, Riga, Latvia.
Werner ZenzDepartment of General Paediatrics, Medical University of Graz, Graz, Steiermark, Austria.
Michael LevinSection of Paediatric Infectious Diseases, Imperial College London, London, UK.
Clementien VermontDepartment of Paediatric Infectious Diseases and Immunology, Erasmus MC Sophia Children's Hospital, Rotterdam, Nederland, The Netherlands.
Henriette A MollGeneral Paediatrics, Erasmus MC Sophia Children's Hospital, Rotterdam, Zuid-Holland, The Netherlands h.a.moll@erasmusmc.nl.ORCID 0000-0001-9304-3322
Erasmus MC - Sophia Children’s Hospital · NLImperial College London · GBLjubljana University Medical Centre · SIMedical University of Graz · ATNational and Kapodistrian University of Athens · GRNewcastle upon Tyne Hospital · GBRadboud University Nijmegen · NLErasmus MC · NLGerman Center for Infection Research · DEImperial College Healthcare NHS Trust · GBUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo develop and cross-validate a multivariable clinical prediction model to identify invasive bacterial infections (IBI) and to identify patient groups who might benefit from new biomarkers.

designProspective observational study.

setting12 emergency departments (EDs) in 8 European countries. PATIENTS: Febrile children aged 0-18 years.

main outcome measuresIBI, defined as bacteraemia, meningitis and bone/joint infection. We derived and cross-validated a model for IBI using variables from the Feverkidstool (clinical symptoms, C reactive protein), neurological signs, non-blanching rash and comorbidity. We assessed discrimination (area under the receiver operating curve) and diagnostic performance at different risk thresholds for IBI: sensitivity, specificity, negative and positive likelihood ratios (LRs).

resultsOf 16 268 patients, 135 (0.8%) had an IBI. The discriminative ability of the model was 0.84 (95% CI 0.81 to 0.88) and 0.78 (95% CI 0.74 to 0.82) in pooled cross-validations. The model performed well for the rule-out threshold of 0.1% (sensitivity 0.97 (95% CI 0.93 to 0.99), negative LR 0.1 (95% CI 0.0 to 0.2) and for the rule-in threshold of 2.0% (specificity 0.94 (95% CI 0.94 to 0.95), positive LR 8.4 (95% CI 6.9 to 10.0)). The intermediate thresholds of 0.1%-2.0% performed poorly (ranges: sensitivity 0.59-0.93, negative LR 0.14-0.57, specificity 0.52-0.88, positive LR 1.9-4.8) and comprised 9784 patients (60%).

conclusionsThe rule-out threshold of this model has potential to reduce antibiotic treatment while the rule-in threshold could be used to target treatment in febrile children at the ED. In more than half of patients at intermediate risk, sensitive biomarkers could improve identification of IBI and potentially reduce unnecessary antibiotic prescriptions.

Indexed as

Anti-Bacterial AgentsBacteremiaBacterial InfectionsBiomarkersChildChild, PreschoolClinical Decision RulesC-Reactive ProteinEmergency Service, HospitalEuropeFemaleFeverHumansInappropriate PrescribingInfantMaleAnti-Bacterial AgentsBiomarkersC-Reactive Proteinepidemiologytherapeutics

Identifiers

PMID33208397
PMCPMC8237171
OpenAlexW3096152753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.